Analytical and Bioanalytical Chemistry

, Volume 410, Issue 6, pp 1833–1843 | Cite as

Storage stability study of porcine hepatic and intestinal cytochrome P450 isoenzymes by use of a newly developed and fully validated highly sensitive HPLC-MS/MS method

  • Wim Schelstraete
  • Mathias Devreese
  • Siska Croubels
Research Paper

Abstract

Microsomes are an ideal medium to investigate cytochrome P450 (CYP450) enzyme-mediated drug metabolism. However, before microsomes are prepared, tissues can be stored for a long time. Studies about the stability of these enzymes in porcine hepatic and intestinal tissues upon storage are lacking. To be able to investigate CYP450 stability in microsomes prepared from these tissues, a highly sensitive and rapid HPLC-MS/MS method for the simultaneous determination of six CYP450 metabolites in incubation medium was developed and validated. The metabolites, paracetamol (CYP1A), 7-hydroxy-coumarin (CYP2A), 1-hydroxy-midazolam (CYP3A), 4-hydroxy-tolbutamide (CYP2C), dextrorphan (CYP2D), and 6-hydroxy-chlorzoxazone (CYP2E) were extracted with ethyl acetate at pH 1.0, followed by evaporation and separation on an Agilent Zorbax Eclipse Plus C18 column. The method was fully validated in a GLP-compliant laboratory according to European guidelines and was highly sensitive (LOQ = 0.25–2.5 ng/mL), selective, had good precision (RSD-within, 1.0–9.1%; RSD-between, 1.0–18.4%) and accuracy (within-run, 83.3–102%; between-run, 78.5–102%), and showed no relative signal suppression and enhancement. Consequently, this method was applied to study the stability of porcine hepatic and intestinal CYP450 isoenzymes when tissues were stored at − 80 °C. The results indicate that porcine CYP450 isoenzymes are stable in tissues at least up to 4 months when snap frozen and stored at − 80 °C. Moreover, the results indicate differences in porcine CYP450 stability compared to rat, rabbit, and fish CYP450, as observed by other research groups, hence stressing the importance to investigate the CYP450 stability of a specific species.

Keywords

HPLC-MS/MS Pig Cytochrome P450 Stability Liver Intestine 

Notes

Acknowledgements

This work was supported by the Ghent University Special Research Fund grant BOF. DOC.2015.0075.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Welfare of animals

All procedures followed were in accordance to the ethical standards of the ethical committee of the Faculties of Veterinary Medicine and Bioscience Engineering of Ghent University. The pigs were subject to the approval with number EC2015_113.

References

  1. 1.
    Nelson DR, Kamataki T, Waxman DJ, Guengerich FP, Estabrook RW, Feyereisen R, et al. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol. 1993;12(1):1–51.CrossRefGoogle Scholar
  2. 2.
    Lewis DFV. 57 varieties: the human cytochromes P450. Pharmacogenomics. 2004;5(3):305–18.CrossRefGoogle Scholar
  3. 3.
    Guengerich FP. Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J. 2006;8(1):101–11.CrossRefGoogle Scholar
  4. 4.
    Yuan R, Madani S, Wei X-X, Reynolds K, Huang S-M. Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos. 2002;30(12):1311–9.CrossRefGoogle Scholar
  5. 5.
    Yamazaki H, Inoue K, Turvy CG, Guengerich FP, Shimada T. Effects of freezing, thawing, and storage of human liver samples on the microsomal contents and activities of cytochrome p450 enzymes. Drug Metab Dispos. 1997;25(2):168–74.Google Scholar
  6. 6.
    Förlin L, Andersson T. Storage conditions of rainbow trout liver cytochrome p-450 and conjugating enzymes. Comp Biochem Physiol. 1985;80(3):569–72.Google Scholar
  7. 7.
    Pearce RE, Mcintyre CJ, Madan A, Sanzgiri U, Draper AJ, Bullock PL, et al. Effects of freezing , thawing, and storing human liver microsomes on cytochrome P450 activity. Arch Biochem Biophys. 1996;331(2):145–69.CrossRefGoogle Scholar
  8. 8.
    Tredger JM, Chhabra RS. Preservation of various microsomal drug metabolizing components in tissue preparations from the livers, lungs and small intestines of rodents. Drug Metab Dispos. 1976;4(5):451–9.Google Scholar
  9. 9.
    Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism 1. J Pharmacol Exp Ther. 1997;283(3):1552–62.Google Scholar
  10. 10.
    Swindle MM, Makin A, Herron AJ, Clubb FJ, Frazier KS. Swine as models in biomedical research and toxicology testing. Vet Pathol. 2012;49(2):344–56.CrossRefGoogle Scholar
  11. 11.
    Bode G, Clausing P, Gervais F, Loegsted J, Luft J, Nogues V, et al. The utility of the minipig as an animal model in regulatory toxicology. J Pharmacol Toxicol Methods. 2010;62(3):196–220.CrossRefGoogle Scholar
  12. 12.
    Vaclavikova R, Soucek P, Svobodova L, Anzenbacher P, Simek P, Guengerich FP, et al. Different in vitro metabolism of paclitaxel and docetaxel in humans, rats, pigs, and minipigs. Drug Metab Dispos. 2004;32(6):666–74.CrossRefGoogle Scholar
  13. 13.
    Gasthuys E, Vandecasteele T, De Bruyne P, Vande Walle J, De Backer P, Devreese M, et al. the potential use of piglets as human pediatric surrogate for preclinical pharmacokinetic and pharmacodynamic drug testing. Curr Pharm Des. 2016;22:1–17.Google Scholar
  14. 14.
    Anzenbacher P, Soucek P, Anzenbacherová E, Gut I, Hrubý K, Svoboda Z, et al. Presence and activity of cytochrome P450 isoforms in minipig liver microsomes; comparison with human liver samples. Drug Metab Dispos. 1998;26(1):56–9.Google Scholar
  15. 15.
    Skaanild MT. Porcine cytochrome P450 and metabolism. Curr Pharm Des. 2006;12(11):1421–7.CrossRefGoogle Scholar
  16. 16.
    Matal J, Tunkov A, Iller M, Anzenbacherov E, Anzenbacher P. Isolation of two cytochrome P450 forms, CYP2A19 and CYP1A, from pig liver microsomes. J Vet Pharmacol Ther. 2009;32(5):470–6.CrossRefGoogle Scholar
  17. 17.
    Anzenbacherová E, Baranová J, Zuber R, Pechová A, Anzenbacher P, Soucek P, et al. Model systems based on experimental animals for studies on drug metabolism in man: (mini)pig cytochromes P450 3A29 and 2E1. Basic Clin Pharmacol Toxicol. 2004;95:244–5.Google Scholar
  18. 18.
    Puccinelli E, Gervasi PG, Longo V. Xenobiotic metabolizing cytochrome P450 in pig, a promising animal model. Curr Drug Metab. 2011;12(6):507–25.CrossRefGoogle Scholar
  19. 19.
    De Bock L, Boussery K, Colin P, De Smet J, T’jollyn H, Van Bocxlaer J. Development and validation of a fast and sensitive UPLC-MS/MS method for the quantification of six probe metabolites for the in vitro determination of cytochrome P450 activity. Talanta. 2012;89:209–16.CrossRefGoogle Scholar
  20. 20.
    Dinger J, Meyer MR, Maurer HH. Development and validation of a liquid-chromatography high-resolution tandem mass spectrometry approach for quantification of nine cytochrome P450 (CYP) model substrate metabolites in an in vitro CYP inhibition cocktail. Anal Bioanal Chem. 2014;406(18):4453–64.CrossRefGoogle Scholar
  21. 21.
    Lee KS, Kim SK. Direct and metabolism-dependent cytochrome P450 inhibition assays for evaluating drug–drug interactions. J Appl Toxicol. 2013;33(2):100–8.CrossRefGoogle Scholar
  22. 22.
    Kim M-J, Kim H, Cha I-J, Park J-S, Shon J-H, Liu K-H, et al. High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2005;19(18):2651–8.CrossRefGoogle Scholar
  23. 23.
    Shi R, Ma B, Wu J, Wang T, Ma Y. Rapid and accurate liquid chromatography and tandem mass spectrometry method for the simultaneous quantification of ten metabolic reactions catalyzed by hepatic cytochrome P450 enzymes. J Sep Sci. 2015;38(19):3363–73.CrossRefGoogle Scholar
  24. 24.
    He F, Bi H, Xie Z, Zuo Z, Li J, Li X, et al. Rapid determination of six metabolites from multiple cytochrome P450 probe substrates in human liver microsome by liquid chromatography/mass spectrometry: application to high-throughput inhibition screening of terpenoids. Rapid Commun Mass Spectrom. 2007;21:635–43.CrossRefGoogle Scholar
  25. 25.
    Li X, Chen X, Li Q, Wang L, Zhong D. Validated method for rapid inhibition screening of six cytochrome P450 enzymes by liquid chromatography-tandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci. 2007;852:128–37.CrossRefGoogle Scholar
  26. 26.
    Walsky RL, Obach RS. Validated assays for human cytochrome P450 activities. Drug Metab Dispos. 2004;32(6):647–60.CrossRefGoogle Scholar
  27. 27.
    Kostiainen R, Kauppila TJ. Effect of eluent on the ionization process in liquid chromatography–mass spectrometry. J Chromatogr A. 2009;1216:685–99.CrossRefGoogle Scholar
  28. 28.
    Goossens J, De Bock L, Osselaere A, Verbrugghe E, Devreese M, Boussery K, et al. The mycotoxin T-2 inhibits hepatic cytochrome P4503A activity in pigs. Food Chem Toxicol. 2013;57:54–6.CrossRefGoogle Scholar
  29. 29.
    Guerre P, Eeckhoutte C, Burgat V, Galtier P. The effects of T-2 toxin exposure on liver drug metabolizing enzymes in rabbit. Food Addit Contam. 2007;17:1019–26.CrossRefGoogle Scholar
  30. 30.
    Bailey DG, Malcolm J, Arnold O, Spence JD. Grapefruit juice–drug interactions. Br J Clin Pharmacol. 1998;46:101–10.CrossRefGoogle Scholar
  31. 31.
    Bradford MM. A rapid and sensitive method for the quantitation microgram quantities of protein utilizing the principle of protein–dye binding. Anal Biochem. 1976;72:248–54.CrossRefGoogle Scholar
  32. 32.
    Commision Decision of 12 August 2002 implementing Council Directive 96/23/EC concerning the performance of analytical methods and the interpretation of results. Off J Eur Communities. 2002;L221:8–36.Google Scholar
  33. 33.
    Knecht J, Stork G. Prozentuales und logarithmisches Verfahren zur Berechnung von Eichkurven. Fresenius’ Z Anal Chem. 1974;99(270):97–9.Google Scholar
  34. 34.
    Wilson ZE, Rostami-Hodjegan A, Burn JL, Tooley A, Boyle J, Ellis SW, et al. Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver. Br J Clin Pharmacol. 2003;56(4):433–40.CrossRefGoogle Scholar
  35. 35.
    Osselaere A, De Bock L, Eeckhaut V, De Backer P, Van Bocxlaer J, Boussery K, et al. Hepatic and intestinal CYP3A expression and activity in broilers. J Vet Pharmacol Ther. 2013;36:588–93.Google Scholar
  36. 36.
    Hewavitharana AK. Matrix matching in liquid chromatography–mass spectrometry with stable isotope labelled internal standards—is it necessary? J Chromatogr A. 2011;1218(2):359–61.CrossRefGoogle Scholar
  37. 37.
    Yao M, Dai M, Liu Z, Cui W, Li D, Zhang H, et al. mRNA expression profiles of P450 3A enzymes in the liver and small intestine of the domestic pig. Res Vet Sci. 2012;93(1):360–5.CrossRefGoogle Scholar
  38. 38.
    Guruprasad K, Reddy BVB, Pandit WM. Correlation between stability of a protein and its dipeptide composition: a novel approach for predicting in vivo stability of a protein from its primary sequence. Protein Eng. 1991;4(2):155–61.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Wim Schelstraete
    • 1
  • Mathias Devreese
    • 1
  • Siska Croubels
    • 1
  1. 1.Laboratory of Pharmacology and Toxicology, Department of Pharmacology, Toxicology and Biochemistry, Faculty of Veterinary MedicineGhent UniversityMerelbekeBelgium

Personalised recommendations